The U.S. Food and Drug Administration has begun reviewing the first portion of a new drug application for QTORIN rapamycin, a gel designed to treat microcystic lymphatic malformations, a rare and painful genetic skin condition with no approved therapies. The submission marks a critical step toward what could become the first FDA-approved treatment for the estimated 30,000 or more Americans living with the disease.
Microcystic lymphatic malformations, or microcystic LMs, are caused by faulty signaling in the PI3K/mTOR pathway, leading to malformed lymphatic vessels that can protrude through the skin, leak fluid, bleed, and cause recurrent infections and hospitalizations. Published studies show the condition is progressive and does not improve on its own. QTORIN rapamycin is designed to deliver the drug rapamycin directly to the affected skin tissue, inhibiting the overactive mTOR signaling at the source while limiting absorption into the rest of the body.
In the Phase 3 SELVA study, the treatment produced what the company called highly statistically significant improvements across the primary endpoint, the key secondary endpoint, and all prespecified secondary endpoints. The therapy was also well tolerated. The FDA previously granted Breakthrough Therapy, Fast Track, and Orphan Drug designations to QTORIN rapamycin, recognizing its potential to address a serious unmet medical need.
Pathway to Approval and Launch Plans
The FDA’s rolling review process allows the agency to evaluate completed sections of the application before the full submission is finished. The company expects to submit the remaining modules and complete the application in the second half of 2026. If approved, a standalone commercial launch could follow in the first half of 2027. The company has already begun hiring leaders in commercial, medical affairs, and patient services, including executives with experience launching first-in-disease therapies for rare skin conditions.
In March 2026, the company also launched a disease awareness campaign called BEYOND mLM in collaboration with patient advocacy groups, aiming to help physicians recognize the condition earlier and improve diagnosis rates at vascular anomaly centers.
For patients and families living with microcystic LMs, the submission brings a new sense of possibility. With regulatory review now underway and preparations for a potential launch accelerating, the hope is that a targeted, approved therapy will finally become available for a disease that has long had none.